NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa

This study is being done to determine if compared to placebo, 1800 mg NAC twice a day in patients with RP can reduce loss of cone photoreceptors and delay vision loss over a span of 45 months. It will also determine if there are side effects from long-term use of NAC. This is very important
information for all current and future patients with RP. If NAC is found to be safe and effective it will be a life-long treatment. It is critical that patients know the potential benefits and risks of taking NAC long-term before making such a commitment.